Committee Composition

Robert J. Coury is the executive chairman of Mylan's board of directors. Under his leadership, Mylan has been transformed into one of the largest generics and specialty pharmaceutical companies in the world, serving customers in approximately 150 countries and territories.

Coury was elected to Mylan's board of directors in February 2002, having served since 1995 as a strategic advisor to the company. He became the board's vice chairman shortly after his election and was made CEO of the company in September of that same year, a post he held through 2011.

In 2007, Mylan, under Coury's leadership, went from a U.S. focused company, to a global powerhouse. At the time, Mylan was the third largest generics manufacturer in the U.S. By purchasing India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and acquiring the generics business of Europe-based Merck KGaA, Mylan catapulted to the No. 3 position in the industry worldwide. The acquisition of the former "Merck Generics" gave the company unprecedented scale in many critical areas, including an extensive and unique international commercial footprint.

Prior to these game-changing acquisitions, from 2002-2007, Coury helped further position Mylan to prosper long-term in a consolidating industry marked by increasing competition and growing demand worldwide for high quality, affordable pharmaceuticals. During this pre-globalization period, the company more than doubled its manufacturing capacity; expanded investment in research and development; and maintained Mylan's strong industry leadership on key issues, working with policymakers to help create a more level playing field for producers of generic drugs.

Before Mylan, Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm. Coury earned a Bachelor of Science degree in industrial engineering from the University of Pittsburgh.

Heather Bresch is chief executive officer of Mylan, one of the largest generics and specialty pharmaceutical companies in the world. She also serves on the company’s board of directors.

Mylan’s mission is to provide the world’s 7 billion people access to high quality medicine. Over the course of her 20-year career at the company, Bresch has been a champion of initiatives and policy changes aimed at removing barriers that hinder patient access to high quality medicine. She has testified before the U.S. Congress and the U.S. Food and Drug Administration, among other institutions, on issued related to access to medicine.

Some of Bresch’s key policy priorities include working to ensure that everyone living with HIV/AIDS has access to treatment and advocating for treatment soon after diagnosis to ensure better health outcomes, reduce HIV transmissions and create long-term cost savings. As part of this effort, Bresch has worked to call attention to access issues in developing countries for patients in need of antiretroviral (ARV) treatment for HIV/AIDS. Further, she has helped position Mylan as a leader in the development and manufacture of ARVs. Today, approximately one out of three people in the developing world being treated for HIV/AIDS depends on a Mylan ARV product. 

In other efforts to drive access to medicine, Bresch is actively advocating for the implementation of a viable abbreviated approval pathway for safe and effective generic versions of biologic drugs to provide patients with access to lower-cost versions of life-saving products. She also is working to increase generic drug utilization around the world, particularly in markets where generic utilization rates remain relatively low.

In addition, Bresch is passionate about increasing awareness of food allergies, which can sometimes lead to a life-threatening allergic reaction, called anaphylaxis. She is active in increasing awareness of the risk, symptoms of anaphylaxis, encouraging preparedness to respond when anaphylaxis occurs, and having immediate access to Epinephrine auto-injectors, as Epinephrine is considered the first-line treatment for anaphylaxis.

Bresch also has been a leading advocate for one quality standard for all drugs sold in the U.S. She was instrumental the development of the Generic Drug User Fee Act and advocated for changes to the Federal Food, Drug and Cosmetic Act of 1938 to arm the U.S. Food and Drug Administration with the resources and authority to regularly inspect U.S. and foreign plants at the same rate, both of which were included in the Food and Drug Administration Safety and Innovation Act (FDASIA).

Earlier in her career, Bresch played a vital role in the passage of the 2003 Medicare Modernization Act, a congressional revision to the Hatch-Waxman Act of 1984, which helped to ensure consumer access to affordable pharmaceuticals.

Throughout her career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as Mylan’s president, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s chief operating officer and chief integration officer, leading the successful integration of two transformational and game-changing international acquisitions – Matrix Laboratories and Merck KGaA’s generics business. In addition, Bresch has served as head of Mylan’s North America operations.

Bresch has served two consecutive terms as chairman of the Generic Pharmaceutical Association and one term as its vice chairman. Bresch earned her undergraduate degree from West Virginia University.

Robert Cindrich was appointed to the board of directors of Mylan in March 2011. He is a member of Mylan's Compliance Committee.

Cindrich is a distinguished attorney and former jurist who currently serves as senior advisor to the Office of the President at the University of Pittsburgh Medical Center (UPMC), a global health enterprise. In that role, Cindrich advises UPMC's senior management and board of directors on key corporate governance and strategic business issues. He also is jointly responsible for UPMC's biosecurity initiatives.

Cindrich previously was senior vice president and chief legal officer for UPMC. Before joining UPMC, Cindrich served as a highly respected judge in the U.S. District Court for Western Pennsylvania for 10 years. Prior to that appointment, he was active in both government and private practice, including positions as the Allegheny County Assistant Public Defender and Assistant District Attorney and U.S. Attorney for the Western District of Pennsylvania.

Cindrich also has served as an adjunct professor at the University of Pittsburgh School of Law and at the Duquesne University School of Law. In addition, he is chair of the University of Pittsburgh School of Law's board of visitors, chair of the Heinz History Center, chair of the 21st Century Biodefense Inc. board of directors and a member of the board of directors of UPMC Mercy Hospital. Cindrich also serves on the board of directors and audit committee of Allscripts Healthcare Solutions Inc.

He has belonged to numerous professional organizations, including the American Bar Association, the American Bar Foundation, the Pennsylvania Bar Association, the Allegheny County Bar Association, the American College of Trial Lawyers and the Academy of Trial Lawyers of Allegheny County.

His awards and honors include Jaycee Man of the Year in Law and Government, the Variety Club Pride of Pittsburgh Award, the Joseph F. Weis, Jr. Distinguished Service Award, the Wittenberg University Distinguished Alumni Award and the University of Pittsburgh Legacy Laureate Award.

Cindrich is a graduate of the University of Pittsburgh School of Law. He also served in the U.S. Army Reserves and the U.S. Air Force Reserves.

Melina Higgins is an experienced financier, having served as a partner and in other senior roles at Goldman Sachs during her nearly 20 year career at the firm. Higgins joined Goldman Sachs in 1989 and retired from the firm in January 2010. During her tenure at Goldman Sachs, Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas as well as co-chairperson of the Investment Advisory Committee for the GS Mezzanine Partners funds, which managed over $30 billion of assets and was the global leader in its industry. 

Higgins has significant board experience, having served as a director for numerous companies across a wide range of industries. U.S. Banker ranked Higgins as one of the Top 20 Nonbank Women in Finance. She holds an M.B.A. from Harvard Business School and a B.A. from Colgate University.

Joseph C. Maroon, M.D., was appointed to the board of directors of Mylan in 2003. He is also a member of Mylan's Compensation Committee.

Maroon has  more than 30 years of experience as a practicing neurosurgeon. He is regarded as a premiere specialist in the surgical treatment of injuries and diseases of the brain and spine, particularly with microscopic and minimally invasive procedures. His research into brain tumors, concussions and diseases of the spine have led to many innovative techniques for diagnosing and treating these disorders.

Maroon currently serves as professor, Heindl Scholar in Neuroscience and vice chairman of the Department of Neurosurgery, University of Pittsburgh School of Medicine, where he was previously chief of Neurosurgery from 1972 to 1984. He is on the medical staff of the University of Pittsburgh Medical Center (UPMC) Presbyterian Hospital and Sewickley Valley Hospital and maintains a neurosurgical practice in Wheeling, W.Va.

Prior to rejoining UPMC, Maroon served as professor and chairman of the Department of Neurosurgery at Allegheny General Hospital (AGH) in Pittsburgh from 1984 to 1999 and professor and chairman of the Department of Surgery, at AGH from 1995 to 1998. In 1986,  Maroon was the president of the Congress of Neurological Surgeons, the largest neurological society in North America. He also served on the board of directors of the Think First National Head and Neck Injury Prevention Society and the American Youth Foundation, St Louis, Mo.

Additionally, Maroon has been the team neurosurgeon for the Pittsburgh Steelers since 1981. He is a co-founder of the UPMC Sports Medicine Concussion Program and a co-developer of the world's first computerized sports concussion evaluation system, ImPACT© (Immediate Post-Concussion Assessment and Cognitive Testing), a tool used by team doctors and athletic trainers nationwide to help determine the severity of a concussion and when it is safe for an athlete to return to play following injury.

Maroon has earned numerous awards for his contributions to neurosurgery from various national and international neurological societies throughout his career. He is the author or co-author of 40 book chapters in addition to more than 250 published scientific papers. He has edited three additional books, has given more than 140 national and international presentations, often as a visiting professor, and has served on the editorial boards of five neurological journals. Consistently listed in "America's Best Doctors," Maroon's patients travel from all over the world to seek his care.

Maroon received his undergraduate and medical education at the University of Indiana. Following his graduation from medical school in 1965, he served residencies in neurosurgery at Indiana University, Georgetown University and the Radcliffe Infirmary at Oxford University in England. He received a fellowship from the University of Vermont where he studied microsurgery, as the Given Scholar in Microneurosurgery.

Rajiv Malik is Mylan's president, and is responsible for the company’s operations. He also serves on Mylan’s board of directors.

Malik’s responsibilities as president include overseeing research and development (R&D), business development, regulatory affairs, manufacturing, quality, supply chain,  and medical affairs, as well as the sales and marketing of Mylan’s generics business. He also is responsible for helping lead Mylan’s expansion into emerging and other new commercial markets, such as the company’s commercial launch in India in 2012.

Malik has held important leadership positions at Mylan since January 2007, when the company acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of active pharmaceutical ingredients. At the time of the acquisition, Malik was Matrix's chief executive officer.

Among his earlier contributions at Mylan, Malik played a key role in significantly expanding and diversifying the company’s global product portfolio, pipeline and manufacturing footprint. In partnership with Mylan’s leadership team, he played a significant role in leading the integrations of Mylan and Matrix and Mylan and the generics business of Merck KGaA to leverage the benefits of global scale and vertical and horizontal integration. He also helped establish Mylan as a leader in antiretroviral medicines, particularly in developing markets.

Malik has approximately 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.

Randall "Pete" Vanderveen, Ph.D., was elected to the board of directors of Mylan in 2002. He is a member of the Mylan Compliance Committee.

Vanderveen has served as dean and John Stauffer Chair of the University of Southern California School of Pharmacy since September 2005. From 1998 until 2005, he was dean of the School of Pharmacy, dean of the Graduate School of Pharmaceutical Sciences and professor of Pharmacy at Duquesne University in Pittsburgh. Previously, he served in a variety of academic positions at Oregon State University/Oregon Health Sciences University and Ferris State University.

Vanderveen has practiced pharmacy in independent community pharmacies, chain drug stores, nursing home settings and hospital pharmacies. He is board certified as a psychiatric pharmacist by the Board of Pharmaceutical Specialties.  Vanderveen has served as consultant and advisor to McKesson, Rite Aid, Eckerd, Walgreens, Bristol-Meyers Squibb, UpJohn, Merck and Pfizer.

Vanderveen has also served as a consultant to the Oregon Medical Assistance Program, the Michigan Department of Mental Health, Providence Medical Center, the Veterans Administration Hospital and the Oregon Health Sciences Hospital in Portland, Ore.

Vanderveen was honored as a "Fellow" in both the American Pharmacists Association and the American Society of Health-Systems Pharmacists (ASHP). He is a member and former board of director's member of the American Association of Colleges of Pharmacy and a member of the board of directors of the National Institute on Pharmaceutical Technology and Education (NIPTE). He also served on the Commission on Credentialing for the American Society of Health-Systems Pharmacists. He was selected as "Pharmacist of the Year" by the Michigan Pharmacists Association and has been honored by his alma mater, Purdue University, with a Distinguished Alumnus Award and the Glen A. Sperandio Award for achievement in pharmacy. He is currently a member of the education advisory committee for the National Association of Chain Drug Stores. Vanderveen is a member of the American Association of Pharmaceutical Scientists, the American Society of Consultant Pharmacists, the American College of Clinical Pharmacy, the Academy of Managed Care Pharmacists, the College of Psychiatric and Neurologic Pharmacists and the National Community Pharmacists Association. Vanderveen has published referred articles and book chapters on pharmacokinetics, innovative educational strategies and leadership in nationally recognized journals.

Vanderveen received a bachelor’s of science in pharmacy and a master’s of science in clinical pharmacy from Purdue University. He completed an ASHP-accredited residency at Bronson Medical Center in Kalamazoo, Mich. Vanderveen received his Ph.D. in university administration from Michigan State University.